Huntington's Disease Pipeline Research 2024: Insights About 20+ Companies and 25+ Pipeline Drugs - Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type...
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Yahoo! Finance
This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Huntington's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. "Huntington's disease- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Huntington's disease pipeline landscape is provided which includes the disease overview and Huntington's disease treatment guidelines. The assessment part of the report embraces, in depth Huntington's disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Annexon, Inc. (NASDAQ: ANNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina CongressGlobeNewswire
- Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted PortfolioGlobeNewswire
- Annexon Biosciences to Participate in Upcoming September Investor ConferencesGlobeNewswire
ANNX
Earnings
- 8/12/24 - In-Line
ANNX
Sec Filings
- 9/27/24 - Form S-8
- 9/20/24 - Form 4
- 9/19/24 - Form 144
- ANNX's page on the SEC website